Van Nostrand L. Robert's Insider Trades & SAST Disclosures
Van Nostrand L. Robert's most recent trade in SELLAS Life Sciences Group Inc was a trade of 18,500 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Jan. 10, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Van Nostrand L. Robert.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| SELLAS Life Sciences Group... | Robert L. Van Nostrand | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jan 2025 | 18,500 | 18,500 | - | - | Stock Option (Right to Buy) | |
| SELLAS Life Sciences Group... | Robert L. Van Nostrand | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jan 2025 | 12,500 | 22,900 (0%) | 0% | 0 | Common Stock | |
| Intra-Cellular Therapies Inc | Robert L. Van Nostrand | Director | Grant, award, or other acquisition of securities at price $ 68.49 per share. | 28 Jun 2024 | 83 | 11,340 (0%) | 0% | 68.5 | 5,685 | Common Stock |
| Intra-Cellular Therapies Inc | Robert L. Van Nostrand | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jun 2024 | 1,567 | 0 | - | - | Restricted Stock Units | |
| Intra-Cellular Therapies Inc | Robert L. Van Nostrand | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jun 2024 | 1,567 | 11,257 (0%) | 0% | - | Common Stock | |
| Intra-Cellular Therapies Inc | Robert L. Van Nostrand | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.86 per share. | 18 Jun 2024 | 20,000 | 29,690 (0%) | 0% | 16.9 | 337,200 | Common Stock |
| Intra-Cellular Therapies Inc | Robert L. Van Nostrand | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jun 2024 | 20,000 | 0 | - | - | Stock Option (right to buy) | |
| Intra-Cellular Therapies Inc | Robert L. Van Nostrand | Director | Sale of securities on an exchange or to another person at price $ 76.07 per share. | 18 Jun 2024 | 11,109 | 9,690 (0%) | 0% | 76.1 | 845,062 | Common Stock |
| Intra-Cellular Therapies Inc | Robert L. Van Nostrand | Director | Sale of securities on an exchange or to another person at price $ 75.71 per share. | 18 Jun 2024 | 8,891 | 20,799 (0%) | 0% | 75.7 | 673,138 | Common Stock |
| Intra-Cellular Therapies Inc | Robert L. Van Nostrand | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 4,322 | 4,322 | - | - | Stock Option (right to buy) | |
| Intra-Cellular Therapies Inc | Robert L. Van Nostrand | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 2,951 | 2,951 | - | - | Restricted Stock Units | |
| Intra-Cellular Therapies Inc | Robert L. Van Nostrand | Director | Grant, award, or other acquisition of securities at price $ 69.20 per share. | 31 Mar 2024 | 79 | 9,690 (0%) | 0% | 69.2 | 5,467 | Common Stock |
| Yield10 Bioscience Inc | Robert L. Van Nostrand | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Mar 2024 | 11,924 | 48,635 (2%) | 0% | 0 | Common Stock | |
| Intra-Cellular Therapies Inc | L. Robert Van Nostrand | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.56 per share. | 27 Feb 2024 | 20,000 | 29,611 (0%) | 0% | 18.6 | 371,200 | Common Stock |
| Intra-Cellular Therapies Inc | Robert L. Van Nostrand | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2024 | 20,000 | 0 | - | - | Stock Option (right to buy) | |
| Intra-Cellular Therapies Inc | Van Nostrand L. Robert | Director | Sale of securities on an exchange or to another person at price $ 73.14 per share. | 27 Feb 2024 | 10,349 | 9,611 (0%) | 0% | 73.1 | 756,926 | Common Stock |
| Intra-Cellular Therapies Inc | L. Robert Van Nostrand | Director | Sale of securities on an exchange or to another person at price $ 72.71 per share. | 27 Feb 2024 | 9,651 | 19,960 (0%) | 0% | 72.7 | 701,724 | Common Stock |
| SELLAS Life Sciences Group... | Van Nostrand L. Robert | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jan 2024 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| SELLAS Life Sciences Group... | Robert Van Nostrand L. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jan 2024 | 6,000 | 10,400 (0%) | 0% | 0 | Common Stock | |
| Intra-Cellular Therapies Inc | Van Nostrand L. Robert | Director | Grant, award, or other acquisition of securities at price $ 71.62 per share. | 31 Dec 2023 | 76 | 9,611 (0%) | 0% | 71.6 | 5,443 | Common Stock |
| Yield10 Bioscience Inc | Robert L. Van Nostrand | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Dec 2023 | 18,879 | 36,711 (2%) | 1% | 0 | Common Stock | |
| Yield10 Bioscience Inc | Robert L. Van Nostrand | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Sep 2023 | 13,868 | 17,832 (1%) | 0% | 0 | Common Stock | |
| Yield10 Bioscience Inc | Robert L. Van Nostrand | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2023 | 2,040 | 3,964 (0%) | 0% | 0 | Common Stock | |
| Intra-Cellular Therapies Inc | Robert L. Van Nostrand | Director | Grant, award, or other acquisition of securities at price $ 63.32 per share. | 30 Jun 2023 | 85 | 9,430 (0%) | 0% | 63.3 | 5,382 | Common Stock |
| Intra-Cellular Therapies Inc | Robert L. Van Nostrand | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2023 | 7,009 | 7,009 | - | - | Stock Option (right to buy) | |
| Intra-Cellular Therapies Inc | Robert L. Van Nostrand | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2023 | 1,567 | 1,567 | - | - | Restricted Stock Units | |
| Yield10 Bioscience Inc | Robert L. Van Nostrand | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2023 | 5,000 | 5,000 | - | - | Stock Option (right to buy) | |
| Intra-Cellular Therapies Inc | Robert L. Van Nostrand | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.05 per share. | 17 Apr 2023 | 10,000 | 19,345 (0%) | 0% | 13.1 | 130,500 | Common Stock |
| Intra-Cellular Therapies Inc | Robert L. Van Nostrand | Director | Sale of securities on an exchange or to another person at price $ 63.00 per share. | 17 Apr 2023 | 10,000 | 9,345 (0%) | 0% | 63 | 630,000 | Common Stock |
| Intra-Cellular Therapies Inc | Robert L. Van Nostrand | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Apr 2023 | 10,000 | 0 | - | - | Stock Option (right to buy) | |
| Yield10 Bioscience Inc | Robert L. Van Nostrand | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2023 | 1,642 | 1,924 (0%) | 0% | 0 | Common Stock | |
| Intra-Cellular Therapies Inc | Robert L. Van Nostrand | Director | Grant, award, or other acquisition of securities at price $ 54.15 per share. | 31 Mar 2023 | 95 | 9,345 (0%) | 0% | 54.1 | 5,144 | Common Stock |
| SELLAS Life Sciences Group... | Robert L. Van Nostrand | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2023 | 9,500 | 9,500 | - | - | Stock Option (Right to Buy) | |
| SELLAS Life Sciences Group... | Robert L. Van Nostrand | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2023 | 2,500 | 4,400 (0%) | 0% | 0 | Common Stock | |
| Yield10 Bioscience Inc | Robert L. Van Nostrand | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2022 | 2,109 | 2,109 | - | - | Stock Option (right to buy) | |
| Intra-Cellular Therapies Inc | Robert L. Van Nostrand | Director | Grant, award, or other acquisition of securities at price $ 52.92 per share. | 30 Dec 2022 | 97 | 9,250 (0%) | 0% | 52.9 | 5,133 | Common Stock |
| Yield10 Bioscience Inc | Robert L. Van Nostrand | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2022 | 1,601 | 1,601 | - | - | Stock Option (right to buy) | |
| Intra-Cellular Therapies Inc | Robert L. Van Nostrand | Director | Grant, award, or other acquisition of securities at price $ 46.53 per share. | 30 Sep 2022 | 110 | 9,153 (0%) | 0% | 46.5 | 5,118 | Common Stock |
| Intra-Cellular Therapies Inc | Robert L. Van Nostrand | Director | Sale of securities on an exchange or to another person at price $ 57.15 per share. | 11 Aug 2022 | 28,500 | 10,543 (0%) | 0% | 57.2 | 1,628,775 | Common Stock |
| Intra-Cellular Therapies Inc | Robert L. Van Nostrand | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Aug 2022 | 20,000 | 0 | - | - | Stock Option (right to buy) | |
| Intra-Cellular Therapies Inc | Robert L. Van Nostrand | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.45 per share. | 11 Aug 2022 | 20,000 | 29,043 (0%) | 0% | 12.5 | 249,000 | Common Stock |
| Intra-Cellular Therapies Inc | Robert L. Van Nostrand | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.05 per share. | 11 Aug 2022 | 10,000 | 39,043 (0%) | 0% | 13.1 | 130,500 | Common Stock |
| Intra-Cellular Therapies Inc | Robert L. Van Nostrand | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Aug 2022 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Intra-Cellular Therapies Inc | Robert L. Van Nostrand | Director | Sale of securities on an exchange or to another person at price $ 56.80 per share. | 11 Aug 2022 | 1,500 | 9,043 (0%) | 0% | 56.8 | 85,200 | Common Stock |
| Yield10 Bioscience Inc | Robert L. Van Nostrand | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2022 | 2,134 | 2,134 | - | - | Stock Option (right to buy) | |
| Intra-Cellular Therapies Inc | Robert L. Van Nostrand | Director | Grant, award, or other acquisition of securities at price $ 57.08 per share. | 30 Jun 2022 | 108 | 9,043 (0%) | 0% | 57.1 | 6,165 | Common Stock |
| Intra-Cellular Therapies Inc | Robert L. Van Nostrand | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 16,757 | 16,757 | - | - | Stock Option (right to buy) | |
| Yield10 Bioscience Inc | Robert L. Van Nostrand | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2022 | 5,000 | 5,000 | - | - | Stock Option (right to buy) | |
| Yield10 Bioscience Inc | Robert L. Van Nostrand | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2022 | 908 | 908 | - | - | Stock Option (right to buy) | |
| Intra-Cellular Therapies Inc | Robert L. Van Nostrand | Director | Grant, award, or other acquisition of securities at price $ 61.19 per share. | 31 Mar 2022 | 126 | 8,935 (0%) | 0% | 61.2 | 7,710 | Common Stock |
| SELLAS Life Sciences Group... | Robert L. Van Nostrand | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 7,125 | 7,125 | - | - | Stock Option (Right to Buy) | |
| SELLAS Life Sciences Group... | Robert L. Van Nostrand | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 1,900 | 1,900 (0%) | 0% | 0 | Common Stock | |
| Yield10 Bioscience Inc | Robert L. Van Nostrand | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2021 | 801 | 801 | - | - | Stock Option (right to buy) | |
| Intra-Cellular Therapies Inc | Robert L. Van Nostrand | Director | Grant, award, or other acquisition of securities at price $ 37.28 per share. | 30 Sep 2021 | 215 | 8,661 (0%) | 0% | 37.3 | 8,015 | Common Stock |
| Yield10 Bioscience Inc | Robert L. Van Nostrand | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2021 | 562 | 562 | - | - | Stock Option (right to buy) | |
| Intra-Cellular Therapies Inc | Robert L. Van Nostrand | Director | Grant, award, or other acquisition of securities at price $ 40.82 per share. | 30 Jun 2021 | 173 | 8,446 (0%) | 0% | 40.8 | 7,062 | Common Stock |
| Intra-Cellular Therapies Inc | Robert L. Van Nostrand | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2021 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Yield10 Bioscience Inc | Robert L. Van Nostrand | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2021 | 5,000 | 5,000 | - | - | Stock Option (right to buy) | |
| Yield10 Bioscience Inc | Robert L. Van Nostrand | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2021 | 383 | 383 | - | - | Stock Option (right to buy) | |
| Intra-Cellular Therapies Inc | Robert L. Van Nostrand | Director | Grant, award, or other acquisition of securities at price $ 33.93 per share. | 31 Mar 2021 | 208 | 8,273 (0%) | 0% | 33.9 | 7,057 | Common Stock |
| Yield10 Bioscience Inc | Robert L. Van Nostrand | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2020 | 624 | 624 | - | - | Stock Option (right to buy) | |
| Intra-Cellular Therapies Inc | Robert L. Van Nostrand | Director | Grant, award, or other acquisition of securities at price $ 25.66 per share. | 30 Sep 2020 | 276 | 7,843 (0%) | 0% | 25.7 | 7,082 | Common Stock |
| Yield10 Bioscience Inc | Robert L. Van Nostrand | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2020 | 777 | 777 | - | - | Stock Option (right to buy) | |
| Intra-Cellular Therapies Inc | Robert L. Van Nostrand | Director | Grant, award, or other acquisition of securities at price $ 25.67 per share. | 30 Jun 2020 | 275 | 7,567 (0%) | 0% | 25.7 | 7,059 | Common Stock |
| Yield10 Bioscience Inc | Robert L. Van Nostrand | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2020 | 5,000 | 5,000 | - | - | Stock Option (right to buy) | |
| Intra-Cellular Therapies Inc | Robert L. Van Nostrand | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2020 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Yield10 Bioscience Inc | Robert L. Van Nostrand | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2020 | 1,294 | 1,294 | - | - | Stock Option (right to buy) | |
| Intra-Cellular Therapies Inc | Robert L. Van Nostrand | Director | Grant, award, or other acquisition of securities at price $ 15.37 per share. | 31 Mar 2020 | 460 | 7,292 (0%) | 0% | 15.4 | 7,070 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges